VERADERMICS INC (MANE)
Health Care · biotechnology · NYSE
Veradermics is developing a proprietary, extended-release oral minoxidil treatment aimed at overcoming the safety and efficacy limitations of current hair loss therapies.
What VERADERMICS INC does
Veradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for aesthetic and dermatological conditions. Its lead candidate, VDPHL01, is an oral, extended-release formulation of minoxidil designed to treat pattern hair loss in men and women without inducing the cardiac side effects associated with immediate-release formulations.
Themes: hair restoration, dermatology, aesthetic medicine, extended-release drug delivery
Fundamentals
- Price$127.11 as of 2026-10-20 close
- Market cap$5.3B as of 2026-08-06 (share count; price 2026-10-20)
- P/En/a negative earnings
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.75 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How MANE compares in its sector
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$30M | -$24M | -$0.58 | -$14M† | $21000† |
| Q1 FY2026 2026-03-31 | -$30M | -$27M | -$1.32 | -$21M | $0 |
| Q2 FY2025 2025-06-30 | -$16M | -$16M | -$24.19 | -$16M† | $0† |
| Q1 FY2025 2025-03-31 | -$13M | -$12M | -$19.79 | -$13M | $19000 |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$319M
- Short-term investments$501M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How VERADERMICS INC looks technically
VERADERMICS INC (MANE): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day high about 8 trading days ago.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $109.75 | $109.75 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 136.715. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave upward correction, complete (one of several readings) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($106.51 to $136.72) — its "stochastic" reading is 68 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 68.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
7
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $136.72 (set on 2026-10-08) | $136.72 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $32.00 (set on 2026-02-04) | $32.00 |
| Above the all-time low | it is 297.2% above its all-time low | +297.2% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.86 between its high and its low — about 7.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.86 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $106.54 and $129.24 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $106.54 – $117.89 – $129.24 |
| Typical daily range (% of price) | its price moves about 7.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.0% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.4% |
|---|---|---|
| Open gap | it gapped 6.0% above the previous close 1 session ago and has not traded back through the level it left behind at 108.82 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.0% |
| Gap filled | a 2.6% gap up opened on 2026-10-02 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +16.81% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 18.1 percentage points (the stock gained 19.1% while the market gained 1.0%) | +18.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.2 percentage points (the stock gained 19.9% while the market gained 3.6%) | +16.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 63.3 percentage points (the stock gained 71.8% while the market gained 8.5%) | +63.3% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 4 of the 7 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 7 |
|---|---|---|
| Bearish technical signals | 0 of the 7 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.6% of the share price. | +13.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% above the average price paid since 2026-02-04, so the typical buyer over that stretch is showing a gain. That average is $98.37 — a volume-weighted average of daily closes over 169 sessions, not a true tick-by-tick VWAP. | +29.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% above the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $112.30 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | +13.2% |
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $136.72.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close below $122.00.
This reading has stood for 2 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 50-day moving average · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) · Left an unfilled gap (5%+ in the last week) · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$163.50 range $135.00 – $182.00; median $167.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MANE
- Consensus EPS estimate-$0.5972 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.00591 from -$0.5913, on 2026-09-12, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Success is dependent on the successful completion of clinical trials and receiving FDA approval for VDPHL01.","The company is in the late clinical stage and has not yet generated significant commercial revenue, creating uncertainty regarding its future financial viability.","Potential competition from established pharmaceutical companies with greater resources and existing treatment offerings."]
What changed in the latest 10-Q
AI-assisted comparison of MANE's 10-Q filed 2026-08-11 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (2026-08-11), the milestones achieved 'to date through the second quarter of 2026' section added the Follow-On Public Offering as a completed milestone, whereas in the older filing (2026-05-12) this offering was listed under 'Subsequent to the first quarter of 2026' milestones.
- In the newer filing (2026-08-11), the same milestone list added the Private Placement as a completed milestone under 'to date through the second quarter of 2026', whereas in the older filing (2026-05-12) it was listed under 'Subsequent to the first quarter of 2026' milestones.
- In the newer filing (2026-08-11), a new 'Subsequent to the second quarter of 2026' milestones section was added stating completion of enrollment in the registration-directed Phase 2/3 trial (Study '306') of VDPHL01 in female patients with mild-to-moderate PHL, with topline data expected in the first half of 2027.
- Removed:
- In the older filing (2026-05-12), the 'milestones achieved to date through the first quarter of 2026' section was removed in the newer filing (2026-08-11), and its content was reorganized.
- In the older filing (2026-05-12), a section titled 'Subsequent to the first quarter of 2026, the following milestones have been achieved' was removed in the newer filing (2026-08-11).
- Reworded:
- In the older filing (2026-05-12), the Follow-On Public Offering description stated gross proceeds of approximately $442.0 million before deducting underwriting fees and discounts; the newer filing (2026-08-11) instead states net proceeds of $414.3 million after deducting underwriting discounts, commissions and offering expenses.
- In the older filing (2026-05-12), the Private Placement description stated gross proceeds of approximately $30.0 million before deducting placement agent fees and other expenses; the newer filing (2026-08-11) instead states net proceeds of $28.1 million after deducting placement agent fees and other expenses.
- In the older filing (2026-05-12), the investors in the Private Placement were described as 'certain entities affiliated with Suvretta Capital'; the newer filing (2026-08-11) describes them as 'certain entities affiliated with Montanova Capital (formerly known as Suvretta Capital)'.
- In the older filing (2026-05-12), the Follow-On Public Offering described Common Stock with 'par value $0.00001 per share'; the newer filing (2026-08-11) omits this par value detail.
- In the newer filing (2026-08-11), the opening milestone sentence changed from 'through the first quarter of 2026' to 'through the second quarter of 2026'.
- In the newer filing (2026-08-11), the subsequent milestones sentence changed from 'Subsequent to the first quarter of 2026' to 'Subsequent to the second quarter of 2026'.
- Notes:
- The newer filing text appears truncated at the end of the 'Recent Developments' section, so changes after that point could not be assessed.
- The older filing text appears truncated at the end of the 'Recent Developments' section, so changes after that point could not be assessed.
Risk Factors
- Reworded:
- The newer filing (2026-08-11) updates the net loss figures from 'three months ended March 31, 2026 and 2025 were $27.2 million and $12.4 million, respectively' to 'six months ended June 30, 2026 and 2025 were $50.7 million and $28.0 million, respectively'.
- The newer filing updates the accumulated deficit from '$150.7 million' as of March 31, 2026 to '$174.2 million' as of June 30, 2026.
- Notes:
- The newer filing text is truncated at the end of the section, so changes after the truncation point in the newer filing cannot be assessed.
- Page numbering indicators differ (41 in newer, 36 in older); these are formatting artifacts and were not treated as substantive changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 15 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 15 sells ($103M) — 4 selling insiders
- Last 180 days · read to 2026-10-160 buys · 15 sells ($103M) — 4 selling insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of MANE within a 30-day window between 2026-02-04 and 2026-02-06. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MANE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding MANE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 10,742,037
- Reported value $1,320,626,030
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MANE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MANE had 4,244,476 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
MANE had 10.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.68 days to cover at the same settlement.
- Reported short interest (shares) 4,244,476
- Short interest (% of shares outstanding) 10.2%
- Prior settlement (shares) 4,106,974
- Reported change 3.35%
- Days to cover (reported) 4.68
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Pfizer (PFE)
- Johnson & Johnson (JNJ)
- AbbVie (ABBV)
- Bausch Health (BHC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MANE vs…
VERADERMICS INC is found in…
Frequently asked questions
What does VERADERMICS INC (MANE) do?
Veradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for aesthetic and dermatological conditions. Its lead candidate, VDPHL01, is an oral, extended-release formulation of minoxidil designed to treat pattern hair loss in men and women without inducing the cardiac side effects associated with immediate-release formulations.
What sector is VERADERMICS INC (MANE) in?
VERADERMICS INC (MANE) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are VERADERMICS INC's (MANE) competitors?
Notable peers of VERADERMICS INC (MANE) include Eli Lilly, Pfizer, Johnson & Johnson, AbbVie and Bausch Health. This peer set is informational only — not financial advice.
Is VERADERMICS INC (MANE) overbought or oversold right now?
VERADERMICS INC (MANE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MANE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.